CoChat

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

Open access
Wang, Shuai, Han, Lei, Han, Jungsoo, Li, Peng, Ding, Qing, Zhang, Qing-Jun, Liu, Zhi-Ping, Chen, Chuo, Yu, Yonghao · 2019 · Nature Chemical Biology
Cited by 107

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (PARP1 catalytic inhibition and PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is not well understood. Here we designed a series of small molecule PARP degraders. Treatment with one such compound iRucaparib-AP6 results in highly efficient and specific PARP1 degradation. iRucaparib-AP6 blocks the enzymatic activity of PARP1 in vitro, and PARP1-mediated poly-ADP-ribosylation signaling in intact cells. This strategy mimics PARP1 genetic depletion, which enables the pharmacological decoupling of PARP1 inhibition from PARP1 trapping. Finally, by depleting PARP1, iRucaparib-AP6 protects muscle cells and primary cardiomyocytes from DNA-damage-induced energy crisis and cell death. In summary, these compounds represent ‘non-trapping’ PARP1 degraders that block both the catalytic activity and scaffolding effects of PARP1, providing an ideal approach for the amelioration of the various pathological conditions caused by PARP1 hyperactivation.Small molecules that achieve selective PARP1 degradation were developed that block both the catalytic activity and scaffolding effects of PARP1, enabling the decoupling of PARP1 inhibition and PARP1 trapping.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41589-019-0379-2

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 29

  1. D’Amours, D., Desnoyers, S., D’Silva, I. & Poirier, G. G. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 342, 249–268 (1999). · doi:10.1042/0264-6021:3420249 · Paper page
  2. Hottiger, M. O. Nuclear ADP-ribosylation and its role in chromatin plasticity, cell differentiation, and epigenetics. Annu. Rev. Biochem. 84, 227–263 (2015). · DOI · Paper page
  3. Chambon, P., Weill, J. D. & Mandel, P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 11, 39–43 (1963). · DOI · Paper page
  4. Liu, C., Vyas, A., Kassab, M. A., Singh, A. K. & Yu, X. The role of poly ADP-ribosylation in the first wave of DNA damage response. Nucleic Acids Res. 45, 8129–8141 (2017). · DOI · Paper page
  5. Pommier, Y., O’Connor, M. J. & de Bono, J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci. Transl. Med. 8, 362ps317 (2016). · DOI · Paper page
  6. Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152–1158 (2017). · DOI · Paper page
  7. Berger, N. A. et al. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br. J. Pharm. 175, 192–222 (2018). · DOI · Paper page
  8. Shieh, W. M. et al. Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J. Biol. Chem. 273, 30069–30072 (1998). · DOI · Paper page
  9. Wang, Y., Dawson, V. L. & Dawson, T. M. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp. Neurol. 218, 193–202 (2009). · DOI · Paper page
  10. Burslem, G. M. & Crews, C. M. Small-molecule modulation of protein homeostasis. Chem. Rev. 117, 11269–11301 (2017). · DOI · Paper page
  11. Ferraris, D. V. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J. Med. Chem. 53, 4561–4584 (2010). · DOI · Paper page
  12. Thorsell, A. G. et al. Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors. J. Med. Chem. 60, 1262–1271 (2017). · DOI · Paper page
  13. Yamanaka, H., Penning, C. A., Willis, E. H., Wasson, D. B. & Carson, D. A. Characterization of human poly(ADP-ribose) polymerase with autoantibodies. J. Biol. Chem. 263, 3879–3883 (1988). · doi:10.1016/s0021-9258(18)69007-6
  14. Galdeano, C. et al. Structure-guided design and optimization of small molecules targeting the protein–protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J. Med. Chem. 57, 8657–8663 (2014). · DOI · Paper page
  15. Wahlberg, E. et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat. Biotechnol. 30, 283–288 (2012). · DOI · Paper page
  16. Knezevic, C. E. et al. Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets. Cell Chem. Biol. 23, 1490–1503 (2016). · DOI · Paper page
  17. Ishoey, M. et al. Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders. ACS Chem. Biol. 13, 553–560 (2018). · DOI · Paper page
  18. Zhang, Y., Wang, J., Ding, M. & Yu, Y. Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome. Nat. Methods 10, 981–984 (2013). · DOI · Paper page
  19. Zhen, Y., Zhang, Y. & Yu, Y. A cell-line-specific atlas of PARP-mediated protein Asp/Glu-ADP-ribosylation in breast cancer. Cell Rep. 21, 2326–2337 (2017). · DOI
  20. Pacher, P., Beckman, J. S. & Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87, 315–424 (2007). · DOI · Paper page
  21. Murai, J. & Pommier, Y. PARP trapping beyond homologous recombination and platinum sensitivity in cancers. Annu. Rev. Cancer Biol. 3, 131–150 (2019). · DOI
  22. Dawson, T. M. & Dawson, V. L. Mitochondrial mechanisms of neuronal cell death: potential therapeutics. Annu. Rev. Pharmacol. Toxicol. 57, 437–454 (2017). · DOI · Paper page
  23. Eliasson, M. J. et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med. 3, 1089–1095 (1997). · DOI · Paper page
  24. Yang, Z., Zingarelli, B. & Szabo, C. Effect of genetic disruption of poly(ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock 13, 60–66 (2000). · DOI
  25. Zheng, J., Devalaraja-Narashimha, K., Singaravelu, K. & Padanilam, B. J. Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury. Am. J. Physiol. Ren. Physiol. 288, F387–F398 (2005). · DOI · Paper page
  26. Li, B., Luo, C., Chowdhury, S., Gao, Z. H. & Liu, J. L. Parp1 deficient mice are protected from streptozotocin-induced diabetes but not caerulein-induced pancreatitis, independent of the induction of Reg family genes. Regul. Pept. 186, 83–91 (2013). · DOI
  27. Zhang, Q. J. et al. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J. Clin. Invest. 121, 2447–2456 (2011). · DOI · Paper page
  28. Hu, R. et al. Quantitative secretomic analysis identifies extracellular protein factors that modulate the metastatic phenotype of non-small cell lung cancer. J. Proteome Res. 15, 477–486 (2016). · DOI
  29. James, D. I. et al. First-in-class chemical probes against poly(ADP-ribose) glycohydrolase (PARG) inhibit DNA repair with differential pharmacology to olaparib. ACS Chem. Biol. 11, 3179–3190 (2016). · DOI

Cited by

See all 107

Metadata

Authors
Wang, S., Han, L., Han, J., Li, P., Ding, Q., Zhang, Q.-J., Liu, Z.-P., Chen, C., & Yu, Y.
Venue
Nature Chemical Biology
Published
2019-10-28
Volume
15
Issue
12
Pages
1223-1231
ISSN
  • 1552-4450 (ISSN-L)
  • 1552-4469
OpenAlex
W2981857847
Cited by
107
References
12
FWCI
4.35
Type
journal article
Language
en
Open access
green
Licence
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM122932)
  • Welch Foundation (I-1800)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. https://app.cochat.ai/papers/10.1038/s41589-019-0379-2
The paper
Wang, S., Han, L., Han, J., Li, P., Ding, Q., Zhang, Q.-J., Liu, Z.-P., Chen, C., & Yu, Y. (2019). Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. Nature Chemical Biology. https://doi.org/10.1038/s41589-019-0379-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.